The therapeutic targeting of aromatase, the enzyme responsible for a key step in the biosynthesis of estrogens, has been demonstrated to be among the most effective ways to treat and prevent the recurrence of estrogen‐dependent cancers such as estrogen receptor (ER) positive breast cancers [97]. The gene discussed is CYP19A1; the disease is breast cancer.